I know Tossa mentioned this but there was no change in liver...

  1. 885 Posts.
    lightbulb Created with Sketch.  1
    I know Tossa mentioned this but there was no change in liver steatosis which was a primary endpoint (if I am reading the trial details correctly). If you set that as a primary endpoint and don't meet it, isn't that a big problem? How does the FDA look at something like that going forward for a Phase III?

    I would be interested in Southoz and rgc68's opinion among others.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Last
3.2¢
Change
0.000(0.00%)
Mkt cap ! $10.45M
Open High Low Volume
0.0¢ 0.0¢ 0.0¢ 0

Buyers (Bids)

Vol. Price($)
62064 3.3¢
 

Sellers (Offers)

Price($) Vol.
3.6¢ 39734
Last trade - 11.13am 07/08/2026 (20 minute delay) ?
IMC (ASX) Chart
Day chart unavailable
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.